The review states that "Psilocybin has demonstrated potential in enhancing neuronal plasticity at both the cellular and molecular levels, suggesting promise for Alzheimer’s disease (AD) treatment." It further concludes that "Psilocybin holds potential for conferring distinctive advantages in terms of neuroprotection and cognitive enhancement for individuals with Alzheimer’s disease (AD) through mechanisms such as neuroplasticity, inflammation regulation, and enhanced neuropsychology." The authors note that "its potential as a therapeutic avenue for AD remains largely uncharted" and highlight that an open-label pilot study in patients with mild cognitive impairment or early-stage AD is ongoing.

This official trial record describes an "open-label pilot study" of psilocybin under supportive conditions "for depression in patients with mild cognitive impairment (MCI) or early-stage Alzheimer’s disease." The purpose is stated as examining "whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression" in this population. Participants receive two "moderate to high dose psilocybin administrations" during an 8‑week course, and inclusion criteria require either DSM‑5 Mild or Major Neurocognitive Disorder due to AD or MCI with memory complaints, indicating researchers are actively testing psilocybin as an intervention in people with early Alzheimer’s-related cognitive impairment.

The U.S. National Institute on Aging’s trial listing explains that this pilot study "will evaluate whether psilocybin, provided in a supervised environment, reduces depression and improves the quality of life in people with mild cognitive impairment or early-stage Alzheimer's disease." All participants receive "two doses of psilocybin" plus weekly psychological support, and outcomes include depression and quality-of-life measures over six months. The description identifies psilocybin as "a hallucinogenic chemical" and confirms that Johns Hopkins University is the lead institution, demonstrating that government and academic researchers are formally investigating psilocybin as a potential intervention for symptoms in early AD.

This preclinical study in an AD mouse model reports: "Psilocybin, an FDA‐approved drug for treating major depressive disorder, can restrain neuroinflammation and improve hippocampal neurogenesis." The authors conclude: "Psilocybin treatment can maintain better brain function in an AD model without affecting amyloid‐beta plaques. Improved brain function is likely due to psilocybin‐induced reductions in neuroinflammatory signaling, enhanced hippocampal neurogenesis, and preservation of synapses." They suggest that psilocybin "may represent a potential therapeutic strategy for AD."

This preclinical study reports that "Psilocybin treatment can maintain better brain function in an AD model without affecting amyloid-beta plaques." The authors note that improved brain function "is likely related to preserved synaptic integrity and reduced neuroinflammation," suggesting that psilocybin may exert neuroprotective effects relevant to Alzheimer's pathology. While conducted in an animal model rather than humans, the findings are presented as evidence that psilocybin could have disease-modifying or symptom-modifying potential in AD.

This review article states that it "reviews evidence for effectiveness of natural and synthetic psychedelics in the treatment of AD causes and symptoms." The authors write that preclinical and early clinical data suggest that psychedelics, including psilocybin, may have "potential to modify AD pathology and ameliorate neuropsychiatric symptoms" through mechanisms such as enhanced neuroplasticity and anti-inflammatory effects. They emphasize, however, that controlled clinical trials in AD are still lacking and that current support is mainly based on indirect and preclinical evidence.

This peer‑reviewed case report describes an 80‑year‑old woman with advanced Alzheimer’s disease who received psilocybin and showed "transient multidomain functional improvement" including speech, mobility and self‑care. The authors emphasize that "The findings do not provide conclusive evidence that psilocybin can reverse Alzheimer’s disease" but argue that the case "supports further investigation of psilocybin as a potential symptomatic treatment" and illustrates that psychedelics "may hold promise as an intervention for severe dementia symptoms" that warrants controlled trials.

This paper from Johns Hopkins researchers notes that serotonin 2A receptor agonist "classic psychedelics" are drawing interest as potential treatments and that "preclinical data indicate a potential for low- or high-dose psychedelic treatment regimens to slow or reverse brain atrophy, enhance cognitive function, and slow progression of AD." It further states: "Human clinical research suggests a possible role for high-dose psychedelic administration in symptomatic treatment of depressed mood and anxiety in early-stage AD." The authors present "rationale and potential approaches for preliminary research with psychedelics in patients with AD," highlighting them as "potential novel pharmacotherapies for patients with AD."

This review of psychedelics in neurodegenerative disorders notes growing interest in agents such as psilocybin for conditions including Alzheimer's disease. It summarizes preclinical work showing that psychedelic 5-HT2A agonists can promote structural and functional neuroplasticity, reduce neuroinflammation, and influence pathways like BDNF and mTOR that are implicated in neurodegeneration. The authors suggest these mechanisms provide a "rationale for investigating psychedelics as potential disease-modifying or symptomatic treatments" in disorders like AD, while stressing that clinical evidence in Alzheimer’s patients is currently minimal and largely extrapolated from other indications.

This review on psychedelics and AD notes that neuroinflammation is a key pathological mechanism and that psychedelics, including psilocybin, can modulate it. It states: "In addition to neuroinflammation suppression, psychedelics induce neuroplasticity by increasing brain-derived neurotrophic factor (BDNF) levels and promoting synaptogenesis." The authors discuss psilocybin among compounds that "hold promise as novel interventions targeting neuroinflammation and impaired plasticity in Alzheimer’s disease," while cautioning that clinical validation is still required.

This mechanistic review states that classical psychedelics, including psilocybin, "exert anti-inflammatory effects on microglia and astrocytes" and can reduce levels of pro‑inflammatory cytokines such as TNF‑α and IL‑6 in experimental models. The authors argue that because "chronic neuroinflammation is a hallmark of Alzheimer’s disease," these findings "support the rationale for investigating psychedelics as potential interventions for AD," while underscoring that human data are currently sparse.

This 2024 review states that psychedelics, including LSD and psilocybin, "demonstrated potential in alleviating the symptoms of this incapacitating illness" in the context of Alzheimer's disease-related dementia. The authors write that the "regulated and dosage-specific application of psychedelics represents a groundbreaking therapeutic strategy that merits investigation for the creation of medications targeting AD-related dementia" and that these substances may influence molecular mechanisms relevant to AD, such as BDNF signaling and autophagy regulators. However, they stress that while the area offers "significant promise," additional studies are essential to clarify long-term safety, efficacy, and optimal protocols.

In this viewpoint article, neurologists discuss emerging interest in psychedelic compounds, including psilocybin, as potential therapeutics for neurodegenerative diseases such as Alzheimer's disease. They note that preclinical data on neuroplasticity and mood benefits have prompted "speculation that psychedelics might have disease-modifying or symptomatic benefits" in conditions like AD but emphasize that rigorous clinical trials in these populations are lacking. The authors conclude that while the scientific rationale is intriguing, psychedelics for neurodegenerative disorders "are not yet ready for prime time" and should be pursued within controlled research settings.

Reporting on a UC Berkeley study, the article notes that researchers are investigating whether psilocybin can "support healthy aging by boosting plasticity in the brains of older adults." The PLASTICITY study will use MRI and cognitive testing in adults 60–85 to see how psilocybin affects "memory, perception, emotion, and brain structure and function" and to test whether psychedelics can enhance neuroplasticity. Although participants are cognitively healthy, the researchers frame the work as exploring whether psychedelics could help "protect the aging brain," providing mechanistic support for the idea that psilocybin might eventually be applied to conditions like Alzheimer’s disease.

Discussing a psilocybin case report in advanced dementia, the article states that a woman "appeared to regain speech and independence after psilocybin," but stresses this is "far from proof" and "based on a single case rather than a controlled clinical study." It notes that "there is currently no evidence to suggest that psilocybin reverses" core Alzheimer’s disease processes such as abnormal protein accumulation and neuronal death. The authors acknowledge that psilocybin may temporarily modify communication among surviving brain networks and that other research is exploring how psychedelics affect aging brains, but they caution that "whether these effects translate to individuals with Alzheimer's disease remains uncertain."

Reporting on the Frontiers in Neuroscience case report, the article notes that researchers tested "whether a high dose of psilocybin could help patients with advanced Alzheimer's disease." After one high dose, the patient "temporarily regained several abilities she had lost years earlier," including longer conversations, recognizing some family, improved bladder control, and dressing herself. The article stresses that "the treatment did not reverse the disease" but indicated that some abilities might remain and be temporarily reactivated. It frames psilocybin as "one such candidate" treatment being explored for neurodegenerative and other brain-related disorders.

In its Cognitive Vitality report, the Alzheimer’s Drug Discovery Foundation notes that "the effects of psilocybin on cognitive function have been mixed, with some studies showing a lack of change, some showing impairment, and a few showing [improvement] in some cognitive domains." It summarizes that psilocybin is being studied primarily for depression and anxiety, with orphan drug designation for treatment-resistant depression and major depressive disorder, and that long-term cognitive effects are "not well established." The document does not identify psilocybin as an established treatment for Alzheimer's disease, but it highlights ongoing research and theoretical mechanisms relevant to neurodegeneration.

The Penn Memory Center reports that there are "early investigations of psychedelics as an intervention for Alzheimer’s disease and related dementias (ADRDs)." It notes that researchers at Johns Hopkins "are investigating if psychedelics can help people living with ADRDs cope with their condition" and that their recent work "studies the effect of psilocybin in patients with mild cognitive impairment (MCI) and Alzheimer’s disease." The article states that the therapeutic effects of psychedelics for ADRDs "remain unproven," but researchers believe they could impact neurological causes or associated psychiatric symptoms such as depression and anxiety.

This earlier conceptual review discusses psilocybin among classical psychedelics and states that they "have been shown in preclinical studies to promote structural and functional neuroplasticity and to exert anti-inflammatory effects in the central nervous system." It proposes that such actions "may be harnessed as potential interventions for Alzheimer’s disease and related dementias," particularly for mood and cognitive symptoms, but emphasizes that "rigorous clinical trials in AD populations have not yet been conducted."

Covering the same case, this article explains that "A new case study describes the reversal of symptoms in a woman with advanced Alzheimer’s disease after taking magic mushrooms" and that the findings "hint that psilocybin may temporarily relieve symptoms, at least for some people." Experts quoted stress that this is "a single case report, not proof of Alzheimer’s reversal" and that research into using magic mushrooms to treat dementia "is in its infancy" with "no definitive research" yet. They add that mechanistic ideas are "encouraging" and that psilocybin appears relatively safe in controlled settings, but larger, rigorous studies are needed.

Johns Hopkins researchers describe their trial as a "research study examining a unique approach to depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer’s Disease (AD)." The page explains that they are "studying psilocybin – a psychoactive substance found in certain kinds of mushrooms – to see whether it can help people with depression and Alzheimer’s Disease when administered in a safe and supportive setting." This institutional description confirms that an academic team explicitly views psilocybin as a potential aid or intervention for symptoms in early AD and is testing it in a formal study.

ScienceAlert reports on a Brazilian case study where an 80-year-old woman with advanced Alzheimer's took a high dose of psilocybin-containing mushrooms and "temporarily regained bladder control and the ability to speak beyond monosyllables," with improvements lasting several weeks. The article notes that the authors "warn" the findings "should not be interpreted as a reversal of Alzheimer's pathology" but "raise the possibility that latent functional capacities may persist" and become accessible under psilocybin. It also highlights that neuroscientists worldwide are starting to investigate psilocybin as "a possible new avenue for controlling Alzheimer's symptoms" and mentions a pilot trial testing psilocybin to reduce depression and improve quality of life in early Alzheimer's.

This clinician-written overview notes that "recent studies have demonstrated that psychedelics like psilocybin can stimulate 5-HT2A receptors, promoting cortical neuron growth, activation of neuronal survival mechanisms, and modulation of the immune system." It explains that these drugs increase BDNF and synaptic connectivity, and that "by promoting cortical neuron growth and modulating neuroinflammation, psilocybin may have the potential to simultaneously address two significant components of AD pathophysiology." The piece concludes that evidence is still limited but that psilocybin is "an intriguing candidate for further exploration as a potential treatment for AD."

Contemporary Alzheimer’s research literature describes psilocybin as a "promising" or "potential" therapeutic candidate primarily because of its demonstrated ability in animals and humans to enhance synaptic plasticity, reduce neuroinflammation, and improve mood and coping in serious illness. Review articles typically emphasize that there are, as of 2025–2026, no completed randomized controlled trials of psilocybin in Alzheimer’s disease itself, and that current work is limited to preclinical models, a small open-label pilot trial in early AD or MCI, and individual case reports. This body of work is commonly summarized by researchers as suggesting that psilocybin "has potential" as an intervention for Alzheimer’s-related symptoms but remains experimental.

As of 2026, psilocybin has been granted regulatory designations and advanced into late-stage trials for conditions like treatment-resistant depression and major depressive disorder, but not for Alzheimer's disease. In the AD field, its use is being explored primarily in small pilot studies and case reports targeting neuropsychiatric symptoms (such as depression and anxiety) and hypothesized disease-modifying mechanisms (for example, neuroplasticity and inflammation), with no large randomized controlled trials yet demonstrating efficacy on core Alzheimer's pathology or long-term cognitive outcomes.